Ultime notizie per Annovis Bio (NYSE:ANVS) Azioni

Annovis Bio

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Annovis Bio Inc

Warning: ANVS is at high risk of performing badly

Annovis Bio (ANVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. ...

Buy Rating for Annovis Bio Driven by Promising Regulatory Progress and Potential of Buntanetap

As of November 8, 2024, Annovis had cash and cash equivalents of $13.6 million. The company has an adequate runway for all Phase 3 preparatory stud...

Annovis sees cash runway for Phase 3 preparatory studies, entering AD study

"The third quarter was marked by important milestones outlining the next steps for buntanetap," said Maria Maccecchini, Ph.D., Founder, President, ...

Annovis Bio reports Q3 EPS (97c), consensus (39c)

Annovis Bio GAAP EPS of -$0.97 misses by $0.58

Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on ANVS stock, giving a Buy rating on November 11. Sumant Kulkarni ha...

Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer's Market

ANVS

Health Care

Press Releases

General

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

News

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

Annovis to Host Year-End Investor Webcast on December 11, 2024

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Cabaletta Bio

Chimerix

FibroBiologics

Generation Bio

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immunic

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Invivyd

Leap Therapeutics

MediciNova

Nuvectis Pharma

PMV Pharma

Quince Therapeutics

Renovaro

Regulus Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

D. Boral Capital

HC Wainwright & Co.

Maxim Group

EF Hutton

Rodman & Renshaw

Comments

Annovis Bio

Notizie

Ultime notizie per Annovis Bio (NYSE:ANVS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO